CoChat

Efficacy and Safety of Lixisenatide Once-Daily Morning or Evening Injections in Type 2 Diabetes Inadequately Controlled on Metformin (GetGoal-M)

Open access
Ahrén, Bo, Leguizamo Dimas, Aniceto, Miossec, Patrick, Saubadu, Stéphane, Aronson, Ronnie · 2013 · Diabetes Care

The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.

Abstract

OBJECTIVE: To examine the efficacy and safety of lixisenatide (20 μg once daily, administered before the morning or evening meal) as add-on therapy in patients with type 2 diabetes insufficiently controlled with metformin alone. RESEARCH DESIGN AND METHODS: This was a 24-week, randomized, double-blind, placebo-controlled study in 680 patients with inadequately controlled type 2 diabetes (HbA1c 7–10% [53−86 mmol/mol]). Patients were randomized to lixisenatide morning (n = 255), lixisenatide evening (n = 255), placebo morning (n = 85), or placebo evening (n = 85) injections. RESULTS: Lixisenatide morning injection significantly reduced mean HbA1c versus combined placebo (mean change −0.9% [9.8 mmol/mol] vs. −0.4% [4.4 mmol/mol]; least squares [LS] mean difference vs. placebo −0.5% [5.5 mmol/mol], P < 0.0001). HbA1c was significantly reduced by lixisenatide evening injection (mean change –0.8% [8.7 mmol/mol] vs. –0.4% [4.4 mmol/mol]; LS mean difference –0.4% [4.4 mmol/mol], P < 0.0001). Lixisenatide morning injection significantly reduced 2-h postprandial glucose versus morning placebo (mean change −5.9 vs. −1.4 mmol/L; LS mean difference −4.5 mmol/L, P < 0.0001). LS mean difference in fasting plasma glucose was significant in both morning (–0.9 mmol/L, P < 0.0001) and evening (–0.6 mmol/L, P = 0.0046) groups versus placebo. Mean body weight decreased to a similar extent in all groups. Rates of adverse events were 69.4% in both lixisenatide groups and 60.0% in the placebo group. Rates for nausea and vomiting were 22.7 and 9.4% for lixisenatide morning and 21.2 and 13.3% for lixisenatide evening versus 7.6 and 2.9% for placebo, respectively. Symptomatic hypoglycemia occurred in 6, 13, and 1 patient for lixisenatide morning, evening, and placebo, respectively, with no severe episodes. CONCLUSIONS: In patients with type 2 diabetes inadequately controlled on metformin, lixisenatide 20 μg once daily administered in the morning or evening significantly improved glycemic control, with a pronounced postprandial effect, and was well tolerated.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.2337/dc12-2006

Cites

27 of 27 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Mean HbA1c (A) and mean FPG (B) over 24 weeks with lixisenatide morning once-daily regimen, lixisenatide evening once-daily regimen, and placebo. Data are mean (±SE) as observed for the mITT population. For HbA1c, LS mean change difference vs. placebo at week 24, P < 0.0001 (morning and evening). For FPG, LS mean change difference vs. placebo at week 24, P < 0.0001 (morning) and P = 0.0046 (evening). LOCF, last observation carried forward.
Figure 1 Mean HbA1c (A) and mean FPG (B) over 24 weeks with lixisenatide morning once-daily regimen, lixisenatide evening once-daily regimen, and placebo. Data are mean (±SE) as observed for the mITT population. For HbA1c, LS mean change difference vs. placebo at week 24, P < 0.0001 (morning and evening). For FPG, LS mean change difference vs. placebo at week 24, P < 0.0001 (morning) and P = 0.0046 (evening). LOCF, last observation carried forward.CC BY-NC-ND · PubMed Central
Figure 2 LS mean change in postprandial glucose (A) and glucose excursion (B) from baseline to week 24 (last observation carried forward [LOCF]) with lixisenatide morning and placebo morning once-daily regimens. Data are mean values for the mITT population. Error bars represent the standard error. Glucose excursion calculated as 2-h PPG minus plasma glucose 30 min prior to the meal before study drug administration.
Figure 2 LS mean change in postprandial glucose (A) and glucose excursion (B) from baseline to week 24 (last observation carried forward [LOCF]) with lixisenatide morning and placebo morning once-daily regimens. Data are mean values for the mITT population. Error bars represent the standard error. Glucose excursion calculated as 2-h PPG minus plasma glucose 30 min prior to the meal before study drug administration.CC BY-NC-ND · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 181

Metadata

Authors
Ahrén, B., Leguizamo Dimas, A., Miossec, P., Saubadu, S., & Aronson, R.
Affiliations
  • Lund University, Lund, Sweden
  • Centro de Investigación Clínica del Pacifico, Acapulco, Mexico
  • Sanofi (France) (FR)
  • LMC Diabetes & Endocrinology (Canada) (CA)
Venue
Diabetes Care
Published
2013-08-13
Volume
36
Issue
9
Pages
2543-2550
ISSN
  • 0149-5992 (ISSN-L)
  • 1935-5548
OpenAlex
W2154433510
Cited by
172
References
27
Citations by year
2026: 5 · 2025: 12 · 2024: 5 · 2023: 9 · 2022: 4 · 2021: 4 · 2020: 5 · 2019: 8 · 2018: 9 · 2017: 23 · 2016: 24 · 2015: 17 · 2014: 29 · 2013: 17
FWCI
22.81
Type
journal article
Language
en
Open access
Locations
  • Diabetes Care (publishedVersion, cc-by-nc-nd)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
  • PubMed Central (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
  • Lund University Publications (Lund University) (submittedVersion)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
  • Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
Keywords
lixisenatide, type 2 diabetes, metformin add-on therapy, inadequate glycemic control, HbA1c reduction, postprandial blood glucose, fasting blood glucose, body weight, nausea and vomiting, GLP-1 receptor agonists, injection timing, GIP/GLP-1 receptor agonist
MeSH terms
Glucagon-Like Peptide-2 Receptor, Blood Glucose, Diabetes Mellitus, Type 2, Double-Blind Method, Drug Administration Schedule, Female, Humans, Hypoglycemic Agents, Male, Metformin, Middle Aged, Peptides

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.